Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Edesa Biotech, Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Edesa Biotech, Inc. annual and quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • Edesa Biotech, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Jun 2025 was $1,749,464, a 4.9% decline year-over-year.
  • Edesa Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $7,184,723, a 16% decline from 2024.
  • Edesa Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $6,169,245, a 26% increase from 2023.
  • Edesa Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $8,373,615, a 52% increase from 2022.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Edesa Biotech, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $7,184,723 -$1,015,478 -16% 01 Oct 2024 30 Sep 2025 10-K 12 Dec 2025 2025 FY
2024 $6,169,245 +$2,204,370 +26% 01 Oct 2023 30 Sep 2024 10-K 12 Dec 2025 2025 FY
2023 $8,373,615 +$9,174,509 +52% 01 Oct 2022 30 Sep 2023 10-K 13 Dec 2024 2024 FY
2022 $17,548,124 -$4,205,774 -32% 01 Oct 2021 30 Sep 2022 10-K 15 Dec 2023 2023 FY
2021 $13,342,350 01 Oct 2020 30 Sep 2021 10-K 16 Dec 2022 2022 FY

Edesa Biotech, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $1,749,464 -$81,252 -4.9% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q3
Q1 2025 $1,589,648 +$270,883 +15% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q2
Q2 2024 $1,668,212 +$316,694 +16% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q3
Q1 2024 $1,860,531 +$473,018 +20% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q2
Q2 2023 $1,984,906 +$3,802,114 +66% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q3
Q1 2023 $2,333,549 +$2,234,967 +49% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q2
Q2 2022 $5,787,020 -$1,027,510 -22% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q3
Q1 2022 $4,568,516 -$2,309,329 -102% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q2
Q2 2021 $4,759,510 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q3
Q1 2021 $2,259,187 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.